$XBIT News

Last published 2w ago

2w agoXBITXBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive OfficersGlobeNewswireAUSTIN, Texas, Oct. 23, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today announced that its Board of Directors have elected Jan-Paul Simard to serve as Co-Chief Executive Officer alongside CEO Dr. Sushma
3w agoXBITXBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal CancerGlobeNewswireInvestigator-sponsored study funded by the French National Cancer Institute (INCa) meets pre-specified primary efficacy success criterion with 61.3% 12-month overall survival. Exploratory Subgroup analysis reveals
4mo agoXBITXBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial SpondyloarthritisGlobeNewswireIND Application for V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path for U.S. Patient Enrollment AUSTIN, Texas, June 15, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today
1y agoXBITWolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities lawsGlobeNewswirePLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION NEW YORK, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights
1y agoXBITXBiotech Pauses Rheumatology programGlobeNewswireAUSTIN, Texas, Dec. 23, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT) announced today data that it is halting its clinical program in rheumatological disease while it seeks to understand the outcome from its recently
2y agoXBITXBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic CancerGlobeNewswireAUSTIN, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer.
2y agoXBITXBiotech to Begin Constructing New R&D Facility on its 48-acre CampusGlobeNewswireAUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it's campus headquarters with the construction of a new, state-of-the-art research and development facility.
2y agoXBITXBiotech Inc. - Appeal, AffirmedUS Patent Trial and Appeal Board
2y agoXBITDr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid ArthritisGlobeNewswireAUSTIN, Texas, Nov. 14, 2023 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT) today announced that Alan Kivitz M.D. is now Lead Investigator & Study Chairman for its clinical research program for Natrunix in Rheumatoid
3y agoXBITXBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeGlobeNewswireAUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury after stroke. The last subject in a
3y agoXBITXBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic CancerGlobeNewswireAUSTIN, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. announced today completion of enrollment of the Phase II portion of its 1-BETTER study—a Phase I/II randomized, double-blind, placebo-controlled clinical
3y agoXBITXBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical TrialGlobeNewswireAUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to evaluate Natrunix as a
3y agoXBITXBIOTECH INC. et al. - Appeal, AffirmedUS Patent Trial and Appeal Board
3y agoXBITFDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsGlobeNewswireAUSTIN, Texas, May 22, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today reports that the FDA's Division of Rheumatology has authorized the Company to initiate a Phase II clinical study to test
3y agoXBITXBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its SharesGlobeNewswireAUSTIN, Texas, May 17, 2023 (GLOBE NEWSWIRE) -- Xbiotech Inc. (NASDAQ:XBIT) ("Xbiotech") announced today that it commenced a "modified Dutch auction" issuer tender offer to purchase up to $80,000,000 in value of its
3y agoXBITXBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeGlobeNewswireAUSTIN, Texas, April 17, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) has enrolled the first subject in a randomized, open-label, placebo-controlled dose escalation clinical study to evaluate safety and
4y agoXBITXBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal CancerGlobeNewswireAUSTIN, Texas, Oct. 13, 2022 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT) announced today the enrollment of the first patient in a multicenter, randomized clinical study for Natrunix in combination with
4y agoXBITXBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer StudyGlobeNewswireAUSTIN, Texas, June 20, 2022 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today it successfully completed the Phase I portion of its 1-BETTER study, a Phase I/II randomized, double-blind, placebo-controlled clinical study to evaluate its a
4y agoXBITNatrunix Versus Methotrexate in Rheumatoid Arthritis - NCT05363917ClinicalTrials.govACR 50 response rate at 12 weeks., ACR 20 response rate at 12 weeks., Mean change in NRS-pain at 12 weeks.
4y agoXBITNatrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis - NCT05363891ClinicalTrials.govACR 50 response rate at 12 weeks., ACR 20 response rate at 12 weeks., Mean change in NRS-pain at 12 weeks
4y agoXBITXBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal CancerGlobeNewswireAUSTIN, Texas, April 28, 2022 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT) announced today that the French National Agency for the Safety of Medicines and Health Products [L'Agence nationale de sécurité du médicament et des produits de santé (ANSM)]
4y agoXBITXBiotech Inks Clinical Manufacturing DealGlobeNewswireAUSTIN, Texas, Feb. 02, 2022 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that it executed Manufacturing Agreement with Janssen Research & Development, LLC to manufacture clinical product, including Bermekimab, a True Human monoclona
4y agoXBITFDA Approves XBiotech's IND in RheumatologyGlobeNewswireAUSTIN, Texas, Dec. 13, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today reports that the FDA's Division of Rheumatology has authorized the Company to commence clinical development of Natrunix, the Company's novel True Human™ antibody cand
5y agoXBITXBiotech to Launch Novel Candidate Therapy for StrokeGlobeNewswireAUSTIN, Texas, Oct. 28, 2021 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT) announced today its plan to commence a randomized, placebo-controlled clinical study to test its new True Human™ antibody therapy for reducing brain injury after stroke. The stu
5y agoXBITHutrukin Safety PK Study - NCT05098080ClinicalTrials.govNumber of subjects with treatment related adverse events assessed according to CTCAE v5.0 of one single intravenous dose of HutrukinTM in healthy subjects at each dose level., Maximum plasma concentration of test article, Plasma concentration at various time points including terminal concentration, (and 2 more...)
5y agoXBITDr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech's Natrunix™ Anti-Cancer Therapy in Pancreatic CancerGlobeNewswireAUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) ("XBiotech") today announced that Benjamin Musher M.D., will chair XBiotech's clinical program for pancreatic cancer. The Company is developing a novel cancer drug, Natrunix
5y agoXBITXBiotech Announces Addition of Dr. Mark Ziats, M.D. Ph.D. as Medical DirectorGlobeNewswireAUSTIN, Texas, Aug. 30, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) ("XBiotech") today announced the addition of Mark Ziats, M.D. Ph.D. as Medical Director. Dr. Ziats will be involved in developing and managing a diverse clinical portfolio fo
5y agoXBITXBiotech Announces Payment of Dividend to Holders of Common StockGlobeNewswireAUSTIN, Texas, July 30, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) ("XBiotech") has completed payment to holders of its Common Stock of a previously announced dividend in the amount of USD$75,000,000.00. Based on the number of shares of Commo
5y agoXBITXBiotech Announces Dividend to Holders of Common StockGlobeNewswireAUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc.'s (NASDAQ:XBIT) ("XBiotech") Board of Directors has declared an extraordinary cash dividend of approximately $2.50 per share, or up to an aggregate of $75 million, to holders of its common
5y agoXBITXBiotech Announces Receipt of $75 Million from Sale of AntibodyGlobeNewswireAUSTIN, Texas, June 30, 2021 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT) announced today it received $75 million from funds escrowed as part of its December 2019 sale of bermekimab. The True Human™ antibody developed by the company to treat inflammat
5y agoXBITXBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic CancerGlobeNewswireAUSTIN, Texas, June 23, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) has enrolled the first patient in its 1-BETTER study, a randomized, double-blind, placebo-controlled clinical study to evaluate XB2001 in combination chemotherapy for treatmen
5y agoXBITFrench National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotech's New Cancer Drug for Colorectal CancerGlobeNewswireAUSTIN, Texas, May 03, 2021 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT) announced today that it had reached an agreement to supply its new cancer drug XB20-01 to INSERM, and its Federation of Digestive Oncology group, a French organization which support
5y agoXBITFDA Gives Go-Ahead for XBiotech's Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic CancerGlobeNewswireAUSTIN, Texas, April 19, 2021 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT) announced today that the FDA has granted permission to commence clinical trials with its novel drug candidate for treating patients with pancreatic cancer. From 1992 to 2018 the d
5y agoXBITXBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging StrainGlobeNewswireAUSTIN, Texas, Jan. 21, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announces that its COVID-19 candidate True Human™ antibody therapy may also be used for treating the COVID-19 mutant...
5y agoXBITXBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke TherapyGlobeNewswireAUSTIN, Texas, Jan. 19, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today the first meeting of its Cerebrovascular Medical Advisory Board (CMAB). The CMAB is comprised of key...
5y agoXBITXBiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influenza-COVID-19 Therapeutic CocktailGlobeNewswireAUSTIN, Texas, Nov. 19, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today new data for its breakthrough candidate therapy for treating infections of influenza and COVID-19. The...
6y agoXBITXBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co-InfectionsGlobeNewswireAUSTIN, Texas, Sept. 21, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today it is developing a new breakthrough candidate therapy it calls FLUVID™ for treating illness caused by...
6y agoXBITXBiotech-Developed COVID-19 Test Supports Convalescent Blood Treatments Now Approved Under FDA Emergency Use AuthorizationGlobeNewswireFDA has Authorized Use of Antibody-Rich COVID-19 Therapy Derived from Convalescent Patients Under Collaboration BioBridge Global Will Be Using XBiotech’s COVID-19 Antibody Test to Identify the...
6y agoXBITXBiotech Discovers COVID-19 Candidate TherapyGlobeNewswireAUSTIN, Texas, Aug. 17, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that it has identified True Human antibodies that could potentially be used as a therapy against...
6y agoXBITXBiotech Achieves Milestone for Production of its New Potential Blockbuster Anti-IL-1⍺ TherapyGlobeNewswireAUSTIN, Texas, July 22, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today it has achieved a crucial milestone in the development of its next generation inflammation-fighting True...
6y agoXBITXBiotech Announces Discovery that Blocking Interleukin-1a Reduces Brain Injury and Neurological Deficit After StrokeGlobeNewswireAUSTIN, Texas, July 14, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today findings published in the prestigious American Heart Association’s journal, Circulation. The publication...
6y agoXBITXBiotech Identifies “Super Bloods” for the Development of a True Human™ COVID-19 TherapyGlobeNewswireDonors with Potent Natural Immunity Against the Virus are Identified as the Starting Point for XBiotech’s Drug Development Program to Treat COVID-19 AUSTIN, Texas, May 01, 2020 (GLOBE NEWSWIRE) --...
6y agoXBITXBiotech Developing Novel True Human Antibody Targeting Interleukin-1alpha (IL-1⍺)GlobeNewswireAUSTIN, Texas, April 14, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that a novel antibody it has discovered that neutralizes interleukin-1 alpha (IL-1⍺) has now been...
6y agoXBITXBiotech and BioBridge Global Collaborate on FDA Program to Develop Potential COVID-19 Treatment Based on Natural Antibodies from Recovered PatientsGlobeNewswireAUSTIN, Texas, April 03, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) and BioBridge Global today announced their collaboration to participate in a U.S. Food and Drug Administration (FDA)...
6y agoXERS XBIT VYGR SUPN+19In Biotech ‘Cash Is King’ When Wall Street Searches for ValueBloombergFor investors looking for deals in biotech, Wall Street firms like Baird advise “cash is king.”
6y agoXBITNew patent application published for: Immunoglobulin Variable Region LibrariesUS Patent Applications (USPTO)( 1 of 1 )
6y agoXBITXBiotech Announces Final Results of Tender OfferGlobeNewswireAUSTIN, Texas, Feb. 19, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the final results of its “modified Dutch auction” tender offer, which expired at 5:00 p.m.,...
6y agoXBITCorrected Press Release: XBiotech Announces Preliminary Results of Tender OfferGlobeNewswireAUSTIN, Texas, Feb. 13, 2020 (GLOBE NEWSWIRE) -- This press release corrects a prior version published on February 13, 2020 and is updated to revise the preliminary proration factor. The corrected...
6y agoXBITXBiotech Announces Preliminary Results of Tender OfferGlobeNewswireAUSTIN, Texas, Feb. 13, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the preliminary results of its “modified Dutch auction” tender offer, which expired at 5:00...
6y agoXBITXBiotech Commences Tender Offer to Purchase up to $420,000,000 of its SharesGlobeNewswireAUSTIN, Texas, Jan. 14, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) announced today that it commenced a “modified Dutch auction” tender offer to purchase up to $420,000,000 of...